ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

GRANUPAS 4 g gastro-resistant granules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet contains 4 g of para-aminosalicylic acid.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Gastro-resistant granules

The granules are small off white/ light brown coloured approximately 1.5 mm diameter.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

GRANUPAS is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology

Adults
4 g (one sachet) three times per day.
The recommended schedule is 4 g every 8 hours. GRANUPAS can be taken with food.
Maximum daily dose is 12 g. Usual duration of treatment is 24 months.

Desensitization
Desensitization can be accomplished by starting with 10 mg para-aminosalicylic acid (PAS) given as a single dose. The dosage is doubled every 2 days until reaching a total of 1 gram after which the dosage is divided to follow the regular schedule of administration. If a mild temperature rise or skin reaction develops, the increment is to be dropped back one level or the progression held for one cycle. Reactions are rare after a total dosage of 1.5 g.

Paediatric population
The optimal dose regimen in children is uncertain. Limited pharmacokinetic data suggest no substantial difference between adults and children.
For infants, children and adolescents the dosage will be adapted to the patient’s weight at 150 mg/kg per day, divided in two intakes. A dosing spoon is provided to measure small doses below 4 g for young children.

The safety and efficacy of para-aminosalicylic acid in neonates have not been established. No data are available.

Method of administration
Oral use.

The contents of the sachet should be added to a glass of orange or tomato juice. They will not
dissolve, but swirling the juice in the glass will help re-suspend the granules if they sink. It should be
drunk at once ensuring that the granules are not left in the glass. Any granules left-over at the bottom
of the glass should be swallowed immediately by adding a small quantity of liquid. Smaller doses in
children should be measured using the dosing spoon and given by sprinkling on apple sauce or yogurt.

The medicinal product should be swallowed immediately after mixing with orange juice, tomato juice,
apple sauce and yogurt whilst the granules are intact.

The granules should not be crushed or chewed, as this impairs the gastro-resistant coating.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Severe renal disease. Patients with severe renal impairment should not receive para-aminosalicylic
acid. Patients with severe renal disease will accumulate the inactive acetyl metabolite of para-
aminosalicylic acid.

4.4 Special warnings and precautions for use

Mild to moderate renal impairment

Given that the metabolites of para-aminosalicylic acid are largely excreted via glomerular filtration,
caution is warranted in patients with mild to moderate renal impairment (see also section 4.3).

Gastric ulcer

Para-aminosalicylic acid should be used with caution in patients with peptic ulcer.

Hepatic impairment

Para-aminosalicylic acid should be used with caution in patients with hepatic impairment.

Hepatic toxicity

Para-aminosalicylic acid may cause hepatitis. The first symptoms usually appear within three months
of the start of therapy with a rash as the most common adverse reaction followed by fever and much
less frequently by gastrointestinal disturbances of anorexia, nausea or diarrhoea. Treatment should be
stopped immediately in this case.

Hypersensitivity

The patient must be monitored carefully during the first three months of therapy and treatment must
be discontinued immediately at the first sign of a rash, fever or other premonitory signs of intolerance.
See section 4.2 for posology adjustments for desensitization.

Hypothyroidism in HIV co-infected patients

Para-aminosalicylic acid may be associated with an increased risk of hypothyroidism in HIV co-
infected patients. Thyroid function should be monitored in HIV co-infected patients before
commencing treatment and regularly during treatment, in particular when para-aminosalicylic acid is
co-administered with ethionamide/prothionamide.
Patients should be advised that the skeletons of the granules may be seen in the stools.

### 4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Results from literature suggest the following:

**Vitamin B12**

Vitamin B12 absorption may be reduced by para-aminosalicylic acid with clinically significant erythrocyte abnormalities developing after depletion; patients on therapy of more than one month should be considered for maintenance of vitamin B12.

**Digoxin**

Para-aminosalicylic acid may decrease the gastrointestinal absorption of digoxin, by inhibiting the absorption function of intestinal cells. Serum digoxin levels should be monitored in patients on concomitant therapy.

**Ethionamide**

Co-administration of para-aminosalicylic acid and ethionamide may intensify adverse reactions of para-aminosalicylic acid, mainly the gastrointestinal effects, including jaundice, hepatitis, nausea, vomiting, diarrhoea, abdominal pain or anorexia. Ethionamide should be withdrawn if these effects are significant.

**Diphenylhydramine**

This medicinal product decreases the gastrointestinal absorption of para-aminosalicylic acid, and should not be administered concomitantly.

**Antiretrovirals**

In a drug-drug interaction study in healthy subjects with para-aminosalicylic acid calcium (PAS-Ca) formulation, the exposure of tenofovir decreased approximately 3-fold when co-administered with multiple doses of 4000 mg PAS-Ca compared with administration of tenofovir alone. The mechanism behind this interaction is unknown. No clinical interaction data is available to determine the relevance of this interaction to the current PAS formulation, but attention should be paid to the potential risk for decreased efficacy of tenofovir when co-administered with para-aminosalicylic acid.

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**

There are no or limited amount of data from the use of para-aminosalicylic acid in pregnant women. Studies in animals have shown some reproductive toxicity (see section 5.3).

GRANUPAS is not recommended during pregnancy and in women of childbearing potential not using contraception.

Literature reports on para-aminosalicylic acid in pregnant women always report co-administration of other medicinal products. As there are no adequate and well controlled studies of para-aminosalicylic acid in humans, para-aminosalicylic acid should be given to a pregnant woman only if clearly needed.

**Breast-feeding**
Para-aminosalicylic acid is excreted in human milk. There is insufficient information on the effects of para-aminosalicylic acid in newborns/infants.

GRANUPAS should not be used during breast-feeding.

**Fertility**

There is no evidence available on the effect of para-aminosalicylic acid on fertility.

**4.7 Effects on ability to drive and use machines**

Para-aminosalicylic acid has negligible influence on the ability to drive and use machines.

**4.8 Undesirable effects**

**Summary of the safety profile**

Most frequent adverse reactions were related to the gastrointestinal system. Cutaneous hypersensitivity reactions were also frequent as well as adverse reactions related to the nervous system.

**Tabulated list of adverse reactions**

In the table below all adverse reactions are listed by system organ class and by frequency. Frequency is defined as very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>Adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td>Very rare</td>
<td>Thrombocytopenia, purpura, leukopenia, anemia, methemoglobinemia, agranulocytosis.</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td>Rare</td>
<td>Hypothyroidism*.</td>
</tr>
<tr>
<td></td>
<td>Very rare</td>
<td>Hypoglycemia.</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td>Very rare</td>
<td>Tendon pain, headache, visual abnormalities, peripheral neuropathy, dizziness.</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Giddiness, vestibular syndrome.</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td>Common</td>
<td>Abdominal pain, vomiting, nausea, bloating, diarrhea, soft stools.</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Anorexia.</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Malabsorption syndrome*, peptic ulcer, gastrointestinal bleeding, jaundice, metallic taste.</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td>Unknown</td>
<td>Hepatitis.</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td>Common</td>
<td>Cutaneous hypersensitivity, skin rash.</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Urticaria.</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td>Very rare</td>
<td>Crystalluria.</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>Very rare</td>
<td>Decreased prothrombine level, hepatocytolysis. Increased blood alkaline phosphatase, transaminases, weight loss.</td>
</tr>
</tbody>
</table>

*see Description of selected adverse reactions below

**Description of selected adverse reactions**

**Hypothyroidism**
Hypothyroidism in HIV co-infected patients is a very common event and occurs in \( \geq 1/10 \) subjects, particularly when para-aminosalicylic acid is administered with ethionamide/prothionamide.

**Malabsorption syndrome**

A malabsorption syndrome can develop in patients on para-aminosalicylic acid, but is usually not complete. The complete syndrome includes steatorrhoea, an abnormal small bowel pattern on x-ray, villus atrophy, depressed cholesterol, reduced D-xylene and iron absorption. Triglyceride absorption is always normal.

**Paediatric population**

Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### 4.9 Overdose

There is no experience with overdose in humans. In the event of overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse reactions and that appropriate symptomatic treatment is instituted immediately.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antimycobacterials, drugs for treatment of tuberculosis, ATC code: J04AA01

**Mechanism of action**

Aminosalicylic acid is bacteriostatic against *Mycobacterium tuberculosis*. It inhibits the onset of bacterial resistance to streptomycin and isoniazid. The mechanism of action of para-aminosalicylic acid resembles the sulfonamides, competing with paraaminobenzoic acid (PABA) for dihydropteroate synthetase (DHP), a key enzyme in the biosynthesis of folates. However, para-aminosalicylic acid appears to be a weak inhibitor of DHP *in vitro*, raising the possibility that it may have a different target.

#### 5.2 Pharmacokinetic properties

**Absorption**

GRANUPAS is a gastro-resistant preparation and, therefore, the acid-resistant coating of the granules protects against degradation in the stomach therefore preventing the formation of meta-aminophenol (a known hepatotoxin). The small granules are designed to escape the restriction on gastric emptying of large particles. Under neutral conditions as are found in the small intestine or in neutral foods, the acid-resistant coating is dissolved within one minute.
Care must be taken in the administration of these granules to protect the acid-resistant coating by maintaining the granules in an acidic food during dosage administration.

Because the granules are protected by an enteric coating, absorption does not commence until they leave the stomach. The soft skeletons of the granules remain and may be seen in the stools.

In a single dose (4 grams) pharmacokinetic study in healthy adult volunteers (N=11) the initial time to a 2 µg/mL serum level of aminosalicylic acid was 2 hours with a range of 45 minutes to 24 hours; the median time to peak was 6 hours with a range of 1.5 to 24 hours; the mean peak level was 20 µg/mL with a range of 9 to 35µg/mL; a level of 2 µg/mL was maintained for an average of 8 hours with a range of 5 to 9.5 a level of 1 µg/mL was maintained for an average of 8.8 hours with a range of 6 to 11.5 hours.

**Distribution**

Para-aminosalicylic acid is distributed in various tissues and fluids including the lungs, kidneys, liver and peritoneal fluid. Pleural or synovial fluid concentrations are approximately equal to plasma. The drug does not cross the blood brain barrier in patients unless the meninges are inflamed, when the concentration of para-aminosalicylic acid in cerebrospinal fluid is about 10 to 50% of the plasma. It is unknown whether it passes through the placental barrier. Small amounts of this agent are distributed in the milk and bile. Plasma protein binding is about 50 to 60%, the kinetic distribution has a half-life of 0.94 hours and a volume of distribution of 1.001 L/kg.

**Biotransformation**

Para-aminosalicylic acid is acetylated in the liver and converted into the inactive metabolite, N-acetyl-para-aminosalicylic acid which is devoid of bacteriostatic activity. The plasma half-life of this agent is about 1 hour, the concentration is not substantially altered in hepatic dysfunction. The concentration of the metabolite may be increased in cases of renal failure.

The major metabolites of PAS are produced by conjugation to glycine in para-aminosalicyluric acid (PASU) for up to 25% of the dose and to N-acetyl in N-acetyl para-aminosalicylic acid (Ac-PAS) for up to 70% of the dose. Together they constitute more than 90% of the total metabolites of PAS found in urine.

**Elimination**

In a single dose study the plasma half-life of para-aminosalicylic acid administered as GRANUPAS was 1.62 ± 0.85 h.

Para-aminosalicylic acid and its metabolites are excreted by glomerular filtration and tubular secretion. The cumulative excretion of para-aminosalicylic after 24 hours is 84% of an oral dose of 4 g, 21% as para-aminosalicylic acid and 63% as the acetylated form. The acetylation process is not genetically determined as is the case for isoniazid.

**5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated dose toxicity.

The data available from a rat embryofoetal development study, where animals were given sodium aminosalicylate (3.85 to 385 mg/kg) were limited. Bone defects were observed at 77 mg/kg only and increased foetal weight was noted at the other doses. Other malformations were observed; however, the exact nature of these findings is unknown. The lack of a dose-response relationship suggests that the findings are not of clinical relevance, but it is noted that the findings were observed at doses below those proposed clinically. In the rabbit, sodium aminosalicylate had no effects on embryofoetal development; however, the doses evaluated were below those proposed clinically.
Sodium aminosalicylic acid was not mutagenic in Ames test strain TA 100. In human lymphocyte cultures in-vitro clastogenic effects of achromatic, chromatid, isochromatic breaks or chromatid translocations were not seen at 153 or 600 µg/mL but at 1500 and 3000 µg/mL there was a dose related increase in chromatid aberrations. An in vivo genotoxicity study (micronucleus test) has been conducted with para-aminosalicylic acid. Results indicate that para-aminosalicylic acid was considered not to have produced any clastogenic effect in mice treated at non-toxic dose levels (examined 24 hours after 2 daily administrations of 312.5 to 1250 mg/kg).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Silica, colloidal hydrated  
Dibutyl sebacate  
Methacrylic acid – Ethyl acrylate copolymer (1:1) Dispersion 30 per cent  
Hypermellose  
Cellulose, microcrystalline  
Talc

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.
The sachets can be stored below 25°C up to 24 hours after first opening.

6.4 Special precautions for storage

Do not store above 25°C.

For storage conditions after first opening of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Sachets consisting of paper/low density polyethylene/aluminium foil/primer/low density polyethylene.

Pack size of 30 sachets. A calibrated measuring spoon is provided.

6.6 Special precautions for disposal and other handling

The sachet should not be used if it is swollen or if the granules have lost their light brown colour, and are turning dark brown or purple.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Eurocept International BV  
Trapgans 5  
1244 RL Ankeveen  
The Netherlands
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/13/896/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 07 April 2014.
Date of latest renewal: 18 December 2018.

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Eurocept International BV
Trapgans 5
1244 RL Ankeveen
The Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

- Additional risk minimisation measures

  None

- Obligation to conduct post-authorisation measures

  None
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON BOX</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. NAME OF THE MEDICINAL PRODUCT</td>
</tr>
<tr>
<td>GRANUPAS 4 g gastro-resistant granules</td>
</tr>
<tr>
<td>para-aminosalicylic acid</td>
</tr>
<tr>
<td>2. STATEMENT OF ACTIVE SUBSTANCE(S)</td>
</tr>
<tr>
<td>Each sachet contains 4 g of para-aminosalicylic acid</td>
</tr>
<tr>
<td>3. LIST OF EXCIPIENTS</td>
</tr>
<tr>
<td>4. PHARMACEUTICAL FORM AND CONTENTS</td>
</tr>
<tr>
<td>Gastro-resistant granules</td>
</tr>
<tr>
<td>30 sachets</td>
</tr>
<tr>
<td>Calibrated measuring spoon</td>
</tr>
<tr>
<td>5. METHOD AND ROUTE(S) OF ADMINISTRATION</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
<tr>
<td>Do not chew or crush.</td>
</tr>
<tr>
<td>Warning: Do not use if sachet is swollen or the granules</td>
</tr>
<tr>
<td>have lost their light brown colour and are dark brown</td>
</tr>
<tr>
<td>or purple</td>
</tr>
<tr>
<td>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE</td>
</tr>
<tr>
<td>STORED OUT OF THE SIGHT AND REACH OF CHILDREN</td>
</tr>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
<tr>
<td>7. OTHER SPECIAL WARNING(S), IF NECESSARY</td>
</tr>
<tr>
<td>8. EXPIRY DATE</td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td>9. SPECIAL STORAGE CONDITIONS</td>
</tr>
<tr>
<td>Do not store above 25°C.</td>
</tr>
</tbody>
</table>
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eurocept International BV (Lucane Pharma)
Trapgans 5
1244 RL Ankeveen
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/13/896/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

GRANUPAS 4 g

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

GRANUPAS 4g gastro-resistant granules
para aminosalicylic acid
Oral use

2. METHOD OF ADMINISTRATION

Do not chew or crush.
Read the package leaflet before use.

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

4 g

6. OTHER

Warning: Do not use if sachet is swollen or the granules have lost their light brown colour and are dark brown or purple.
B. PACKAGE LEAFLET
Package leaflet: Information for the patient
GRANUPAS 4 g gastro-resistant granules
para-aminosalicylic acid

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What GRANUPAS is and what it is used for
2. What you need to know before you take GRANUPAS
3. How to take GRANUPAS
4. Possible side effects
5. How to store GRANUPAS
6. Contents of the pack and other information

1. What GRANUPAS is and what it is used for

GRANUPAS contains para-aminosalicylic acid which is used in adults and children aged 28 days and older to treat resistant tuberculosis in combination with other medicines, in cases of resistance or intolerability with other treatments.

2. What you need to know before you take GRANUPAS

Do not take GRANUPAS

• if you are allergic to para-aminosalicylic acid or any of the other ingredients of this medicine (listed in section 6).
• if you have severe kidney disease.
If you are not sure, talk to your doctor or pharmacist before taking GRANUPAS.

Warnings and precautions
Talk to your doctor or pharmacist before taking GRANUPAS

• if you have liver problems or mild or moderate kidney disease
• if you have a stomach ulcer
• if you are infected with HIV

Children
Use of GRANUPAS is not recommended in newborn babies (under 28 days of age).

Other medicines and GRANUPAS
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

It is especially important to tell your doctor if you are taking any of the following:

• Antituberculosis medicines or ethionamide (other treatments against tuberculosis)
• Vitamin B12
• Digoxin (for heart disease)
- Diphenhydramine (for allergic reactions)
- Tenofovir (for HIV/ hepatitis B infections)

**Pregnancy and breast-feeding**
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. GRANUPAS is not recommended during pregnancy and should only be used if advised by your physician. Do not breastfeed whilst taking GRANUPAS. This is because small amounts of the medicine can pass into mother’s milk.

**Driving and using machines**
GRANUPAS is unlikely to affect your ability to drive any vehicle and use machines. In case it does, please report it to your doctor or pharmacist.

3. **How to take GRANUPAS**
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

**Adults**
The recommended dose for adults is 1 sachet three times a day, with a schedule of 1 sachet every 8 hours. Your physician may need to start with a lower dose to prevent possible side effects. Do not take more than 3 sachets per day. Treatment is usually given for two years (24 months).

- Add the contents of the sachet to a drink of tomato or orange juice.
- Drink straight away
- If some granules are left in the glass, add some more juice and drink straight away.

**Use in infants, children and adolescents**
The dose in infants, children and adolescents will be calculated by your doctor based on the patient’s body weight. The recommended total dose per day is 150 mg for each kg of body weight. This daily amount is divided into two doses spread out through the day.

- Use the spoon that comes with the medicine to measure the dose.
- To measure the dose:
  - Lines on the spoon indicate the amount (in milligrams of para-aminosalicylic acid). Take the correct amount as prescribed by your doctor.
  - Put granules directly into the spoon.
  - Tap the spoon once on a table to give a horizontal level of granules and continue filling if necessary.
- Sprinkle the granules onto apple sauce or yogurt.
- Make your child eat it straight away.

**Taking this medicine**
- Do not crush or chew the granules. Swallow the granules whole. It is important that you do not dissolve, crush or chew the granules as they may not absorb properly and may cause stomach ache or bleeding.
- Do not use the sachet if it is swollen or the granules have lost their light brown colour.
- You may notice granules appearing in your stools; this is normal.
If you take more GRANUPAS than you should
Speak to a doctor or pharmacist.

If you forget to take a dose of GRANUPAS
Do not take a double dose to make up for a forgotten dose. Wait until the next dose is due, then take your normal dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

During the first 3 months of your treatment with GRANUPAS, you must be attentive to any sign of allergic reaction (for example skin eruption, itchy red spots on the skin, itching, rash, watery or itchy eyes or stuffy nose) or hepatitis (for example fever, fatigue, dark urine, pale stool, abdominal pain, yellow skin and eyes). If you experience any of these symptoms, you must contact your doctor immediately.

Common side effects (may affect more than 1 in 100 people):
• giddiness,
• stomach ache (abdominal pain),
• vomiting,
• nausea,
• bloating,
• diarrhoea,
• soft stools,
• skin redness or rash,
• disturbance of gait and equilibrium.

Uncommon side effects (may affect more than 1 in 1,000 people):
• loss of appetite (anorexia).

Rare side effects (may affect more than 1 in 10,000 people):
• thyroid gland problems*,
• reduced ability to absorb nutrients from food ulcer,
• bleeding in the gut,
• yellowing of skin or eyes (jaundice),
• metallic taste,
• itchy rash.

(*) in subjects also infected with HIV thyroid gland problems and specifically underactive thyroid or low levels of thyroid hormones, are a very common side effect that may affect more than 1 in 10 people. Regular monitoring of the thyroid function is indicated for all people living with HIV.

Very rare side effects (may affect less than 1 in 10,000 people):
• reduction in blood platelets,
• red spots on the skin,
• reduction in numbers of white blood cells,
• reduction in numbers of red blood cells,
• reduction of the ability of red blood cells to release oxygen
• low levels of blood sugar,
• tendon pain,
• headache,
• visual abnormalities,
• nerve damage in the hands and feet,
• dizziness,
• crystals in urine.
• prolonged bleeding time,
• destruction of liver cells
• elevated liver enzymes,
• weight loss.

Not known side effects (frequency cannot be estimated from the available data):
• Hepatitis.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store GRANUPAS
Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and sachet after EXP. The expiry date refers to the last day of the month.

Do not store above 25°C. The sachets can be stored below 25°C up to 24 hours after opening.

Do not use this medicine if you notice the sachets are swollen or if the granules are dark brown or purple.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What GRANUPAS contains
The active substance is para-aminosalicylic acid.
Each sachet of gastro-resistant granules contains 4 g of para-aminosalicylic acid.
The other ingredients are silica, colloidal hydrated, dibutyl sebacate, methacrylic acid – ethyl acrylate copolymer (1:1) dispersion 30 per cent, hypromellose, cellulose, microcrystalline, talc.

What GRANUPAS looks like and contents of the pack
This medicine is presented as light brown gastro-resistant granules in sachets.
Each box contains 30 sachets. A calibrated measuring spoon is provided.

Marketing Authorisation Holder
Eurocept International BV
Trapgans 5
1244 RL Ankeveen
The Netherlands

Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Company</th>
<th>Phone Number</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>België/Belgique/Belgien</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>България</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Česká republika</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Danmark</td>
<td>FrostPharma AB</td>
<td>+45 808 20 101</td>
<td><a href="mailto:info@frostpharma.com">info@frostpharma.com</a></td>
</tr>
<tr>
<td>Deutschland</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Eesti</td>
<td>FrostPharma AB</td>
<td>+36 153 868 750</td>
<td><a href="mailto:info@frostpharma.com">info@frostpharma.com</a></td>
</tr>
<tr>
<td>Elláda</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>España</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>France</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Nederland</td>
<td>Eurocept International BV</td>
<td>+31 35 528 39 57</td>
<td><a href="mailto:info@euroceptpharma.com">info@euroceptpharma.com</a></td>
</tr>
<tr>
<td>Norge</td>
<td>FrostPharma AB</td>
<td>+47 815 03 175</td>
<td><a href="mailto:info@frostpharma.com">info@frostpharma.com</a></td>
</tr>
<tr>
<td>Ελλάδα</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Österreich</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Polska</td>
<td>Lucane Pharma</td>
<td>+33 153 868 750</td>
<td><a href="mailto:info@lucanepharma.com">info@lucanepharma.com</a></td>
</tr>
<tr>
<td>Portugal</td>
<td>Overpharma</td>
<td>+351 214 307 760</td>
<td><a href="mailto:info@overpharma.pt">info@overpharma.pt</a></td>
</tr>
</tbody>
</table>
**This leaflet was last revised in**

**Other sources of information**

There are also links to other websites about rare diseases and treatments.
ANNEX IV

SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORIZATION(S)
Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for para-aminosalicylic acid, the scientific conclusions of the CHMP are as follows:

In view of available data on the literature (Parvez et al.) including a study reporting that the para-aminosalicylic acid-calcium formulation significantly reduced systemic exposure to tenofovir, it is considered that such information may be important to prescribers since the data appears to be of reasonable quality with an acceptable cross-over design, and the effect size is very large. In addition, there is no obvious reason why another salt form than that approved would drastically change the interaction potential. Therefore, it is concluded that the product information of products containing para-aminosalicylic acid (centrally authorised product) should be amended accordingly.

The CHMP agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for para-aminosalicylic acid the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing para-aminosalicylic acid (centrally authorised product) is unchanged subject to the proposed changes to the product information.

The CHMP recommends that the terms of the Marketing Authorisation(s) should be varied.